A new report by MarketsandMarkets projects strong growth ahead for the global exosome research market. The market was valued at $144 million in 2021 and is forecast to reach $661 million by 2026, reflecting a compound annual growth rate (CAGR) of 35.6% during the period.
Several key factors are driving this rapid expansion. These include rising investment in pharmaceutical RD and life sciences, high prevalence of cancer globally, and growing interest in exosome-based procedures.
Request for Free Sample Report
Exosomes are tiny vesicles secreted by cells that play a key role in shuttling molecular information between cells. Research into exosomes aims to better understand these communication pathways and leverage exosomes for therapeutic and diagnostic applications.
The report cites increasing pharmaceutical RD spending as a major growth driver. The top pharmaceutical companies continue to invest heavily to bring new drugs and devices to market. While the COVID-19 pandemic temporarily slowed RD growth in 2020, investment is projected to rebound at a 3.2% CAGR between 2019 and 2026, reaching $232.5 billion globally.
Cancer is also fueling demand within the exosome field. Cancer indications comprise the single largest market segment, driven by strong research activity around exosome-based liquid biopsies for cancer diagnosis and treatment monitoring. Lung cancer accounts for the largest revenue share within the cancer segment.
On the services side, rising demand for specialized contract testing services is creating new opportunities. Pharmaceutical companies are outsourcing more testing needs earlier in the drug development cycle to improve efficiency. Services like liquid chromatography, RNA sequencing, and trace metal analysis are increasingly being outsourced and leveraged for exosome applications.
By product segment, kits and reagents dominate the landscape. Key inputs like antibodies, isolation kits, and purification tools are essential for exosome workflows. Kits and reagents made up the largest revenue segment in 2020. Demand is especially strong for isolation and purification kits given their importance in exosome protocols.
Regionally, North America held the largest market share in 2020. Drivers include favorable government funding, supportive regulatory conditions, and a strong foundation of clinical and laboratory research infrastructure. Academic research institutes drive the most demand in North America and globally.
Key players operating in the exosome space include Thermo Fisher Scientific, Bio-Techne, Lonza, QIAGEN, and Miltenyi Biotec. Industry partnerships are accelerating, with major deals in the past two years between Thermo Fisher and Bio-Techne and QIAGEN and Bio-Techne focused on co-developing exosome technologies.
As research continues unlocking the potential of exosomes, this market is poised for massive expansion over the next five years. With exponential CAGR projection through 2026, stakeholders across pharmaceuticals, academia, and biotechnology have immense opportunities to capitalize. Continued RD investment, diagnostic and therapeutic promise in cancer and other diseases, and advanced analytical tools for exosome isolation and analysis will all help accelerate near-term growth.
